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Introduction
The neurobiology of stress-related mood disorders and related anxiety disorders has been extensively studied over the last decades to develop new strategies and effective therapeutic approaches to psychiatric diseases (Catena-Dell'Osso et al., 2013; Kormos and Gaszner, 2013) . However, limited understanding of the pathophysiology of emotional disorders affects the development of novel therapeutic drugs (Catena-Dell'Osso et al., 2013) . Thus, the progression of basic research with respect to the neurobiological mechanisms involved in mood disorders and anxiety is critical to support the development of reliable approaches.
Since corticotropin-releasing factor (CRF) was isolated and characterized as the major physiological regulator of the hypothalamuspituitary-adrenal gland axis and was shown to be responsible for the coordination of the endocrine, autonomic and behavioral responses associated with stress (Vale et al., 1981) , this neuropeptide has become a potential target for the treatment of stress-related mood disorders (Kormos and Gaszner, 2013) . Although the highest concentration of CRF is found in the hypothalamus (Bittencourt and Sawchenko, 2000) , this peptide is widely distributed within the central nervous system, including limbic areas (Cummings et al., 1983) , which reinforces its involvement in the modulation of emotional responses (Anthony et al., 2014; Donatti and Leite-Panissi, 2011; Henry et al., 2006; Klemm, 2001; Radulovic et al., 1999) . In particular, the central nucleus of the amygdala has one of the highest densities of CRF-immunoreactive neurons in the brain (Cummings et al., 1983; Palkovits et al., 1985; Swanson et al., 1983) . The CRF neuropeptide exerts its biological activity by binding to two types of CRF receptors, CRF 1 and CRF 2 receptors (Hauger et al., 2006) . More specifically, whereas a high density of CRF 1 receptors is found in the anterior lobe of the pituitary, neocortex, hippocampus, basolateral nucleus of the amygdala and brainstem (Potter et al., 1994; Sánchez et al., 1999) , CRF 2 receptor expression is more restricted to subcortical structures, including the hypothalamus, amygdala, and brainstem (Lovenberg et al., 1995) .
Fear-like behaviors are produced by intracerebroventricular CRF administration (Meloni et al., 2006; Radulovic et al., 1999) , as well its administration into specific brain areas such as the amygdala (Daniels et al., 2004; Donatti and Leite-Panissi, 2011) , the periaqueductal gray matter (Martins et al., 1997) , the hippocampus (Radulovic et al., 1999) , and the lateral septum (Bakshi et al., 2002) . In this way, while antagonist CRF 1 receptors have pronounced effects in normalizing stressinduced anxiety when CRF is released, CRF 2 receptors appear be involved in the expression of both stress-induced anxiety and spontaneous anxiety behavior (Takahashi, 2001) . Moreover, although preclinical data using CRF 1 receptor antagonists in experimental animal models were unclear concerning their antidepressant activity (Nielsen, 2006) , this receptor is considered to be possible target for the treatment of psychiatric diseases (Arborelius et al., 1999; Heinrichs et al., 1997; Reul and Holsboer, 2002) . Additionally, previous study has shown that the activation of neurons that express CRF 2 in the lateral septum promotes persistent anxious behavior, as evaluated by the light-dark box test, the open field test and the novel object test in mice (Anthony et al., 2014) .
Many studies have used paradigms based on animal models to understand human emotional behavior because it appears to be correlated with fear-and anxiety-related defensive patterns in non-human mammals (Blanchard et al., 2001) . In this case, defensive reactions are used to study the neural substrate of the modulation of innate fear and anxiety responses (Canteras, 2003) . Defensive reactions are triggered based on prey-predator distance (Ratner, 1967) and on the degree of threat posed by the situation (Blanchard and Blanchard, 1988) . Therefore, when a predator or other dangerous stimulus is very close to the prey and physical contact is possible, behavioral responses such as fight or flight are exhibited. However, when physical contact is prolonged and there is no chance to escape, the prey's last attempt to survive is the tonic immobility (TI) response, or "death feigning" (Klemm, 2001) .
The tonic immobility (TI) response is an innate and reversible defensive response characterized by profound physical inactivity and relative lack of responsivity to environmental stimuli (Klemm, 2001; Ratner, 1967) . This behavior is shown during situations of extreme, inescapable threat (Gallup, 1977) and is observed in many species of invertebrate and vertebrate animals (Klemm, 2001; Ratner, 1967) including humans (Volchan et al., 2011) . In fact, previous studies have suggested that tonic immobility can predict the severity of posttraumatic stress disorder (PTSD) symptoms (Fiszman et al., 2008; Lima et al., 2010; Rocha-Rego et al., 2009) .
During the TI response, neurovegetative and behavioral alterations are observed, including vocalizations, intermittent eye closure, muscular stiffness, parkinsonism-like tremors (Jones, 1986) , and alterations in neural activity (Rusinova and Davydov, 2010) as well as changes in heart rate, breathing (Giannico et al., 2014) , and body temperature (Eddy and Gallup, 1990) . The neurophysiological events that occur while TI is exhibited have been observed in aversive emotional states and resemble innate fear (Nash et al., 1976) . Recently, Alves and colleagues (Alves et al., 2014) have demonstrated a positive correlation between heart rate changes after viewing trauma-related pictures and tonic immobility scores in individuals exposed to a traumatic event. This innate fear response can be induced in the laboratory by a manual inversion and restriction of animal movements; tactile and proprioceptive sensations are essential to trigger TI behavior (Gallup, 1977; Klemm, 2001) . Regarding the neural substrates involved in TI modulation, previous studies have shown that distinct structures of the central nervous system, such as the periaqueductal gray matter (Vieira et al., 2011 ), hypothalamus (De Oliveira et al., 1997 , and amygdaloid complex Leite-Panissi, 2011, 2009; Leite-Panissi et al., 2006 , 2003 Leite-Panissi and Menescal-de-Oliveira, 2002) , are intimately related to the modulation of this behavior. In this context, distinct neurotransmitter systems, including CRF receptors in the central (CeA) or basolateral (BLA) nucleus of the amygdala, can alter TI duration. This effect is possibly due to the modulation of fear and anxiety but is not due to increased spontaneous motor activity, which may affect TI behavior nonspecifically (Donatti and (Donatti and Leite-Panissi, 2011) showed that the activation of CRF receptors in the BLA or CeA increased the TI response, whereas treatment with a nonselective CRF antagonist, alpha-helical-CRF 9-41 , decreased this innate fear response. So, these data support the role of the amygdaloid CRF system in the control of emotional responses; however, further experiments are required to understand the interplay between CRF receptors and the TI response to provide support for the development of new drugs to treat emotional disorders in humans.
Based on the finding described above, the present study was designed to investigate the effects of specific CRF receptors, CRF 1 and CRF 2 , in the BLA and CeA on the duration of TI in guinea pigs (Cavia porcellus). To this end, we evaluated whether administration of the CRF 1 receptor antagonist CP-376395 or the CRF 2 receptor antagonist Astressin 2B into the BLA or CeA could alter TI duration. Additionally, we investigated whether previous microinjection of CP-376395 or Astressin 2B into the BLA or CeA could modify the CRF-induced increase in TI behavior.
Materials and methods

Ethics statement
The experiments were carried out in compliance with the recommendations of international guides for animal use with the approval of the Animal Care and Use Committee of the University of São Paulo-Brazil, Campus of Ribeirão Preto (Protocol number 12.1.1393.53.0). All efforts were made to minimize animal suffering.
Animals
Adult male guinea pigs (Cavia porcellus, from the University of São Paulo, Campus of Ribeirão Preto, Brazil) weighing 400-500 g (n = 114) were kept in Plexiglas wall cages (56 cm × 17 cm × 39 cm, five guinea pigs per cage) in a room maintained at 24 ± 1°C, on a 12 h light cycle, with free access to water and food throughout the experimental period.
Tonic immobility recording
Each guinea pig was submitted to five maneuvers of TI induction and the duration of each episode was recorded. Induction of TI was attempted by holding the guinea pig around the thorax with the hands, then quickly inverting the animal and pressing the animal down into a shaped plywood trough (25 cm long × 15 cm high). The pressure applied by the experimenter was proportional to the resistance offered by the guinea pig during the restraining maneuver. When the guinea pig stopped moving, the experimenter slowly withdrew his hand and a chronometer was activated to measure the duration of the response (in seconds). The response was considered to be finished when the guinea pig resumed an upright position. If the guinea pig did not become motionless within 60 s, the duration of the episode was recorded as zero. For group analysis, the mean of each guinea piǵs five episodes was used.
Surgical procedures
One day after the control TI experiment, the guinea pigs were anesthetized by an intramuscular injection of ketamine (100 mg/kg) plus xylazine (14 mg/kg) and placed in a stereotaxic apparatus (David-Kopf Instruments, USA) with the buccal piece 21.4 mm below the interauricular line. One guide cannula (14 mm in length and 0.6 mm in diameter, prepared from a hypodermic needle) was implanted into the left hemisphere toward the BLA or the CeA nuclei. According to the Rössner (Rössner, 1965) atlas for guinea pig, the stereotaxic coordinates for the placement of the guide cannula implanted toward the BLA were 3.4 mm caudal to the bregma, 6.0 mm lateral to the midline, and 9.0 mm below the cortical surface. For the CeA, the coordinates were 3.4 mm caudal to the bregma, 6.1 mm lateral to the midline, and 7.5 mm below the cortical surface. The guide cannula was lowered to a depth of 1 mm above the target regions and fixed to the skull by means of a self-polymerizing resin and an additional anchoring screw. At the end of surgery, each guide cannula was sealed with a stainless-steel wire to protect it from obstruction. In addition, the guinea pigs received a subcutaneous injection of the anti-inflammatory and analgesic Banamine (Schering-Plough, flunixin meglumine, 2.5 mg/kg, 10 mg/ml, 0.2 ml). Afterwards, the guinea pigs were given a period of 1 week to recover from the surgical procedure.
Experimental groups of tonic immobility
Seven days after the recovering from surgery, the guinea pigs were submitted to a TI session (five testing episodes) without drug administration for the postoperative control experiment (SHAM). Then, the animals were divided in distinct experimental groups and two protocols for each brain area (BLA and CeA) in order to evaluate the effects of the drugs. The first protocol was to evaluate the action of blockade of CRF 1 receptors in BLA or in CeA. Two groups (n = 7 BLA; n = 7 CeA) received CP-376395 at doses of 0.4 μg/0.2 μl or 0.8 μg/0.2 μl, at two consecutive days. Other two groups (n = 6 BLA; n = 6 CeA) received CRF (0.2 μg/0.2 μl) on one day and then, on a second day, CP-376395 0.4 μg/0.2 μl followed 5 min later by CRF (0.2 μg/0.2 μl). The two tests days were separated by 24 h. To evaluate the role of specific antagonist CRF 2 receptors (Astressin 2B) two groups (n = 5 BLA; n = 5 CeA) received Astressin 2B at doses of 0.4 μg/0.2 μl or 0.8 μg/0.2 μl at two consecutive days. Other two groups (n = 6 BLA; n = 7 CeA) received CRF (0.2 μg/0.2 μl) on one day and then, on a second day, Astressin 2B 0.4 μg/0.2 μl followed 5 min later by CRF (0.2 μg/0.2 μl). The two tests days were separated by 24 h.
When CRF 1 or CRF 2 antagonists were administered in two consecutive days, the dose used in the first day was chosen randomly and the administration of the following day was counterbalanced. Similarly, the treatment with CRF itself or preceded by CRF 1 or CRF 2 antagonists was chosen randomly for the first day and counterbalanced in the following day.
To evaluate the spatial specificity of the effect of the drugs on TI episodes, the drugs were microinjected around the nucleus studied (n = 10).
Motor activity
To exclude the possibility that CP-376395, Astressin 2B or the administration of these antagonists administered before CRF altered the TI response nonspecifically by increasing or decreasing spontaneous activity, motor activity was measured 5 min after each treatment. Five groups to each brain site (BLA or CeA) were used in order to rule such possibility. Thus, in these experimental groups the guinea pigs were implanted with unilateral cannula toward the BLA or the CeA. After 6 days for complete recovery, a group received saline 0.9% at a volume of 0.2 μl (n = 5 BLA; n = 6 CeA), then CP-376395 at dose of 0.8 μg/ 0.2 μl (n = 5 BLA; n = 6 to CeA), Astressin 2B at dose of 0.8 μg/0.2 μl (n = 5 BLA; n = 6 to CeA), CP-376395 at dose of 0.4 μg/0.2 μl followed by CRF 0.2 μg/0.2 μl (n = 5 to BLA; n = 6 to CeA), Astressin 2B at dose of 0.4 μg/0.2 μl followed by CRF 0.2 μg/0.2 μl (n = 5 to BLA; n = 6 to CeA). Then, the open-field test was conducted. The test was performed in a polyethylene box (60 cm × 60 cm × 60 cm) with the ground divided into 16 equal squares of 15 cm each. Immediately after the treatment, the guinea pig was placed in the center of the box and locomotor activity was evaluated by direct observation of the number of squares crossed per minute during a 5-min period.
Drugs and microinjection procedure
The chosen drugs CP-376395 (a selective CRF 1 antagonist, Tocris), Astressin 2B (a potent relatively selective CRF 2 antagonist, SigmaAldrich A5227) and corticotrophin-releasing factor (CRF, SigmaAldrich C3042) as well as the doses used in the study were based on previous reports (Donatti and Leite-Panissi, 2011; Henry et al., 2006; Miguel et al., 2014; Zorrilla et al., 2013) . All drugs were freshly dissolved in (0.9% NaCl) normal saline. The microinjections were performed with a Hamilton microsyringe (10 μl) connected to a PE-10 polyethylene catheter, which in turn was coupled to a thin dental needle (0.3 mm O.D.; 0.1 mm longer than the guide cannula). A volume of 0.2 μl was microinjected over a period of 1 min and the needle was left in place for an additional 40 s to avoid reflux.
Histological verification
After the end of the experiments, the guinea pigs were given a lethal dose of chloral hydrate (500 mg/kg, i.p.) and intracardially perfused with saline followed by 10% formalin. Then, the brains were removed and fixed in 10% formalin for 24 h and then were cryoprotected in sucrose 30% for 3 days, afterward which the brains were frozen in isopentane at −40°C. Subsequently, 40 μm coronal sections were cut by cryostat, mounted on gelatinized slides and Nissl-stained in order to localize the sites of injections, according to Rössner atlas (Rössner, 1965) . Only the guinea pigs with microinjections that reached the target structure were used for data analysis.
Statistical analysis
Data of TI behavior are reported as the means ± standard error of the means (SEM) of the mean duration of five episodes of TI. Due to variability and bias in the TI duration data, a natural logarithmic transformation was performed on all duration scores prior to statistical analysis. The results of locomotor activity are reported as the means ± SEM of the number of squares crossed during the 5-min period in the open-field test. The data were analyzed by a repeated measures analysis of variance (ANOVA). The degree of freedom of the repeated measure (treatment) was corrected by Huynh-Feldt ε parameter. The difference between the treatments were determined by post hoc test Newman-Keuls, with the level of significance set at P < 0.05.
Results
The present results showed that microinjection of CP-376395 (CRF 1 receptor antagonist) or Astressin 2B (CRF 2 receptor antagonist) into the BLA or CeA (at a dose of 0.8 μg) decreased the duration of TI in guinea pigs (Fig. 1A-D) . In addition, treatment with 0.4 μg of CP-376395 or 0.4 μg of Astressin 2B followed by the injection of 0.2 μg of CRF into the BLA or CeA prevented the increase in TI induced by the activation of CRF receptors in these areas ( Fig. 2A-D) .
Regarding the CRF 1 receptor antagonist, a repeated-measures ANOVA revealed significant differences between treatment doses (F 6,27 = 6.99, P < 0.01) in the group that received CP-376395 microinjection into the BLA (Fig. 1A) . A Newman-Keuls post hoc test showed a significant difference between the 0.8 μg dose of the CRF 1 receptor antagonist (CP-376395) and the control and sham (P < 0.05); however, there was no difference compared to the 0.4 μg dose. Nevertheless, no differences were observed among the control, sham and the 0.4 μg dose of CP-376395. Similarly, there was a significant difference between the doses of CP-376395 microinjected into the CeA (F 6,27 = 8.629, P < 0.001, ANOVA). The 0.8 μg CP-376395 treatment differed significantly from the control, sham and 0.4 μg CP-376395 treatments according to the Newman-Keuls post hoc test (P < 0.05, Fig. 1C ). No differences were observed among the control, sham and 0.4 μg CP-376395 treatments.
A repeated-measures ANOVA revealed significant differences among the treatments (F 3,19 = 10.800, P < 0.05) in the group that received Astressin 2B (ASTR 2B) microinjection into the BLA. A Newman-Keuls test demonstrated a significant difference (P < 0.05) between the 0.8 μg ASTR 2B treatment and the control, sham and 0.4 μg ASTR 2B treatments (Fig. 1B) . No differences, however, were found among the control, sham and 0.4 μg ASTR 2B treatments. Likewise, there was a significant difference between the doses of ASTR 2B injected into the CeA (F 4,19 = 4.575, P < 0.05). A Newman-Keuls test demonstrated a significant difference (P < 0.05) between the 0.8 μg ASTR 2B treatment and the control and sham treatments (Fig. 1D ). No differences, however, were found among the control, sham and 0.4 μg ASTR 2B treatments or between the injections of 0.8 μg ASTR 2B and 0.4 μg ASTR 2B into the CeA (Fig. 1D) .
As shown in a previous report (Donatti and Leite-Panissi, 2011 ), microinjection of CRF into the BLA or CeA of the guinea pig increased the duration of TI episodes compared to control episodes ( Fig. 2A-D) . However, when the microinjection of CRF into the BLA or CeA was preceded by the injection of CP-376395 (0.4 μg) or ASTR 2B (0.4 μg) into these areas, the effect of CRF was blocked. A repeated-measures ANOVA revealed a significant difference between treatments (F 6,27 = 6.03, P < 0.05; F 5,23 = 8.482, P < 0.005, into the BLA and CeA, respectively) when CRF was preceded by the CRF 1 receptor antagonist (CP-376395). A Newman-Keuls post hoc test demonstrated that the treatment with CRF differed (P < 0.05) from the control, sham and CP-376395 + CRF treatments in the BLA ( Fig. 2A) and CeA (Fig. 2C) . However, there was no difference between the control, sham and CP-376395 + CRF treatments in these areas. Similarly, a repeated-measures ANOVA revealed a significant difference between treatments (F 6,27 = 3.630, P < 0.05; F 5,23 = 8.430, P < 0.02, into the BLA and CeA, respectively) when CRF was preceded by the CRF 2 receptor antagonist (Astressin 2B). A Newman-Keuls post hoc test showed that the treatment with CRF differed (P < 0.05) from the control, sham and ASTR 2B + CRF treatments in the BLA (Fig. 2B) and CeA (Fig. 2D) . No differences were observed among the control, sham and ASTR 2B + CRF treatments in both areas.
Finally, unilateral microinjection of CP-376395, Astressin 2B, CP-376395 + CRF or ASTR 2B + CRF into the BLA (Fig. 3A) or CeA Fig. 1 . Modulation of the tonic immobility (TI) response by the CRF 1 and CRF 2 receptor antagonists in the basolateral (BLA) or central (CeA) nuclei of the amygdala. (A) Means ± SEM TI duration pre-surgery (CONT), post-surgery (SHAM) and after microinjection of CRF 1 receptor antagonist CP-376395 (CP 37) at 0.4 μg and 0.8 μg doses for two consecutive days into the BLA (n = 7). (B) Means ± SEM TI duration pre-surgery (CONT), post-surgery (SHAM) and after microinjection of CRF 2 receptor antagonist Astressin 2B (ASTR 2B) at 0.4 μg and 0.8 μg doses for two consecutive days into the BLA (n = 5). (C) Means ± SEM TI duration pre-surgery (CONT), post-surgery (SHAM) and after microinjection of CRF 1 receptor antagonist CP-376395 (CP 37) at 0.4 μg and 0.8 μg doses for two consecutive days into the CeA (n = 7). (D) Means ± SEM TI duration pre-surgery (CONT), post-surgery (SHAM) and after microinjection of CRF 2 receptor antagonist Astressin 2B (ASTR 2B) at 0.4 μg and 0.8 μg doses for two consecutive days into the CeA (n = 5). The vertical bars indicate the SEM. # P < 0.05, for Newman Keuls test comparing with respective control and sham. * P < 0.05, for Newman Keuls test comparing the respective control, sham and 0.4 μg of CP 37 or 0.4 μg ASTR 2B.
( Fig. 3B) did not significantly alter spontaneous motor activity in the open field test (F 4,24 = 0.148, P > 0.05; F 4,29 = 0.290, P > 0.05 in the BLA and CeA, respectively, ANOVA) compared with the guinea pigs that received saline microinjections into the BLA or CeA. Fig. 4 illustrates the sites of the microinjections made in the BLA and CeA for all experimental groups, as well as nearby sites where drugs had no effect.
Discussion
The major finding of the study is that the modulation of fear and anxiety mediated by the CRF system in the BLA and CeA occurs through concomitant effects on CRF 1 and CRF 2 receptors.In details, the blockade of CRF 1 and CRF 2 receptors in the BLA and CeA produces a decrease in fear and/or anxiety, as suggested by decreased TI duration in guinea pigs. This decrease does not appear to be due to a modification of spontaneous motor activity, which may affect TI duration nonspecifically. Additionally, antagonists for CRF 1 and CRF 2 receptors were able to prevent the increase in TI duration induced by CRF administration at the same sites.
TI behavior is an innate response triggered by sensorial stimuli and intense fear (Klemm, 2001; Ratner, 1967) . This unconditioned response occurs in a wide range of species, included humans (Volchan et al., 2011) , and has served as a model to study anxiety and depression (Fiszman et al., 2008; Lima et al., 2010; Olsen et al., 2002; Rocha-Rego et al., 2009) . From this perspective, previous studies have shown that the activation of CRF receptors in the BLA promotes an increase in related responses to fear and anxiety (Sajdyk et al., 1999) ; the same occurs in the CeA (Skórzewska et al., 2009) , including an increase in TI response in guinea pigs (Donatti and Leite-Panissi, 2011) . Together, these results suggest that an increase of CRF release in the amygdala and the activation of CRF receptors serve as a neural substrate for fearlike reactions (Sajdyk and Gehlert, 2000; Skórzewska et al., 2009) .
According to Graeff (Graeff, 1990) , innate fear is mediated by neural circuitry that consists of at least the amygdala, medial hypothalamus and periaqueductal grey matter. In particular, the BLA has been considered to be a structure closely related to emotional responses to fear, stress and anxiety and may be responsible for the perception of aversive stimuli (Sajdyk and Shekhar, 1997a,b; Sanders and Shekhar, 1991) . In turn, the CeA is related to afferents to central nervous system components, which are responsible for the autonomic and somatic components that occur in fear-related reactions (Davis, 1998) . Generally, the amygdaloid complex contributes to fear and anxiety responses by assigning emotional and motivational significance to sensorial stimuli (Ledoux, 2000) .
Corticotropin-releasing factor (CRF) is involved in the coordination of autonomic and endocrine responses and behavioral responses to stress (Carrasco and Van De Kar, 2003; Vale et al., 1981) . Indeed, the release of CRF and subsequent secretion of glucocorticoids plays a central role in an organism's preparation to cope with imminent injuries, particularly when faced with ambiguous cues such as those elicited by aversive environment (Merali et al., 2004) . Additionally, it is important to note that CRF has an essential role in the fight or flight responses, increases heart rate and glucocorticoid levels, inhibits digestive function (Dunn and Berridge, 1990) and still leads to anxiety (Takahashi et al., 1989) . The effects of CRF are mediated by coupling to CRF 1 and CRF 2 receptors (Hauger et al., 2006; Hillhouse and Grammatopoulos, 2006) . In particular, CRF 1 receptors can be found in several brain areas including pituitary, brain stem, cerebellum, amygdala, and cortex. CRF 2 receptors have a similar distribution pattern in the reshus monkey brain with the exception of increased densities in the brain regions including the neocortex, amygdala and hippocampal formation (Sánchez et al., 1999) . Additionally, while the activation of CRF 1 receptors has been related to increased reactions to stress and anxiety (Fekete and Zorrilla, 2007) , the involvement of CRF 2 and the relationship between CRF 1 and CRF 2 in emotional modulation have not been fully clarified (Zorrilla et al., 2013) . From this perspective, the present study indicates that blocking either CRF 1 or CRF 2 in the BLA and CeA had a similar effect on fear and anxiety modulation because the administration of CP-376395 (the CRF 1 receptor antagonist) or Astressin 2B (the CRF 2 receptor antagonist) in these areas promoted a reduction of the TI response, an innate fear behavior. So, we hypothesize that both CRF receptors, CRF 1 and CRF 2 , are activated by endogenous CRF, which is released during TI behavior. Taking into account that TI response is considered a last resort aimed at the survival of the animal (Gallup, 1977; Klemm, 1971 ) the combined action of Fig. 3 . The effects of CRF 1 and CRF 2 receptor antagonists microinjected into the basolateral amygdala (BLA) or into the central amygdala (CeA) of guinea pigs on motor activity for a 5 min in the open field test. Motor activity was assessed after microinjection of 0.9% saline (SAL, 0.2 μl), CRF 1 receptor antagonist CP-376395 (CP 37, 0.8 μg), CRF 2 receptor antagonist Astressin 2B (ASTR 2B 0.8 μg), or CRF (0.2 μg) preceded by CP-376395 (CP 37, 0.4 μg) or CRF (0.2 μg) preceded by Astressin 2B (ASTR 2B, 0.4 μg). The vertical bars indicate the SEM. The numbers above the bars represent the number of guinea pigs used in each group. CRF 1 and CRF 2 receptors can be crucial for emission of the appropriate defensive response. Indeed, CRF 1 and CRF 2 share functions in emotional responses, and inhibition of both receptors promotes a stronger decrease in stress-induced behavior than inhibition of either receptor alone (Takahashi, 2001) . Moreover, the combined action of CRF 1 and CRF 2 has been suggested since the emotional behavior can be mediated by CRF 1 receptor activation and modulated by CRF 2 receptors (Cook, 2004; Reul and Holsboer, 2002) . It is important to note that CRF 1 may be activated during acute stress and early phases of anxiety disorders (Coric et al., 2010; Ising et al., 2007) , as well the administration of Astressin 2B into the lateral septum did not have an effect on anxiety-like behavior in low-stress conditions but had an anxiolytic-like effect when animals were submitted to restraint stress (Henry et al., 2006) . Thus, it is possible to suggest that the TI modulation in guinea pigs sharing similar mechanisms with acute stress and spontaneous anxiety rather than with chronic states where stable anxiety levels have been established. Reinforcing this hypothesis, the urocortin 1-cointaining neurons of Edinger-Westphal nucleus were only activated in response to acute restraint stress (de Andrade et al., 2014) as well this nucleus has shown high densities of FOS-immunoreactivity cells induced by TI response in guinea pigs (Vieira et al., 2011) . In line with this view, Coric et al. (2010) have shown that CRF 1 receptor antagonist did not have significant anxiolytic properties in a placebo controlled trial in generalized anxiety disorders. Further, in a preclinical model of anxiety disorders CRF antagonists blocked stress-mediated amygdala alterations in the early stages of plasticity, but were ineffective once full plasticity and a chronic anxiety state was established (Rainnie et al., 2004) .
Consistent with our data, a recent study has shown that transient CRF 2 activation in neurons located in the lateral septum promotes persistent anxious behavior, probably due to the positive regulation of corticosteroid levels (Anthony et al., 2014) . So, we speculate it is possible that blockade of CRF 1 and CRF 2 in the BLA or CeA promoted an alteration of corticosteroid levels along with reduction of innate fear, which, in turn, reduced the TI response in guinea pigs. Indeed, TI response susceptibility is positively correlated with corticosterone plasma levels suggesting the involvement of the pituitary-adrenocortical axis in modulation of this behavior (Carli et al., 1979) .
In contrast to our results related to CRF 2 , Skórzewska and colleagues (Skórzewska et al., 2011) reported that intracerebroventricular administration of CRF 2 -selective antagonists (antisauvagine-30 or Astressin 2B) increased a conditioned fear freezing response and the conditioned fear-elevated concentration of serum corticosterone. These authors suggested that a selective blockade of CRF 2 receptors could facilitate the conduction of signals via CRF 1 receptors, and may contribute to the enhancement of anxiety-like responses. From this point of view, our results are distinct, possibly because the TI response is an emotional behavior critical for survival in the environment (Klemm, 2001; Ratner, 1967) ; therefore, it is elicited in high-stress situations, and under these conditions, CRF 2 receptors are essential (Henry et al., 2006) . In line with the present data, a previous report has shown that overexpression of the CRF 2 receptor in the bed nucleus of the stria terminalis improves posttraumatic stress disorder-like symptoms (Elharrar et al., 2013) . This result suggests that the CRF 2 receptor promotes anxiety-like responses rather than reduces anxiety-related behavior. So, blockade of the CRF 2 receptor in the BLA or CeA probably reduced fear and anxiety, as suggested by the decrease in the TI response.
From the same perspective, previous studies by Sajdyk and colleagues (Sajdyk et al., 1999) and Spiga and colleagues (Spiga et al., 2006) have shown that the administration of CRF or urocortin 1 (a selective agonist for CRF 1 and CRF 2 receptors but with a higher affinity for the CRF 1 receptor) into the BLA produced an anxiogenic effect, as evaluated by a social interaction test in rats; this effect was reversed by the antagonism of CRF 1 receptors. Again, intracerebroventricular or systemic injections of non-peptidic CRF 1 antagonists (CP-154,526, antalarmin or DMP696) reduced defensive behavior in the elevated plus maze test and light/dark test [for review Bale and Vale (2004) and Carrasco and Van De Kar (2003) ]. However, intra-septal, intracerebroventricular or systemic injections of CRF 1 agonists attenuated defensive behavior (Radulovic et al., 1999) . The study of Iemolo et al. (2013) strongly support the anxiolytic effect of CeA CRF 1 blockage. They reported that a selective CRF1 antagonist (R121919) in CeA blocked the anxiogenic effect induced by palatable food withdrawn in a model for food intake in rats (Iemolo et al., 2013) . Further, another finding showed that the administration of CRF 2 receptor antagonists (antisauvagine-30) in the BLA was not effective in reducing fear responses in aversive conditioning (Hubbard et al., 2007) . However, the administration of Astressin 2B into the medial amygdala decreased Tmaze avoidance latencies, an anxiolytic-like effect (Alves et al., 2016) . Together, these results support the involvement of CRF 1 and CRF 2 receptors in the modulation of fear and anxiety behaviors, but the ways in which these responses are modulated should be clarified. It is possible that the differences in behavioral effects are related to the independent neural circuits that mediate the distinct ethologic models correlated with defensive responses (Lowry and Moore, 2006) .
Regarding the mechanism of action of CRF, several studies have shown that low doses of CRF may preferentially activate CRF 1 receptors in glutamatergic projection neurons, serotoninergic neurons or glutamatergic collaterals in the medial prefrontal cortex (Vertes, 2004) . Indeed, prosencephalic inactivation of CRF 1 receptors (where glutamatergic neurons are highly expressed) reduced the emission of defensive responses (Refojo et al., 2011) . It is important to note that both BLA and CeA have large numbers of glutamatergic neurons (McEwen and Wingfield, 2003) , and glutamate receptors have been found to colocalize with CRF in the amygdala (Śmiałowska et al., 2002) . In particular, previous studies have shown that BLA can modulate CeA efferents via direct projections to the medial subnucleus of the CeA (CeAm) as well through an indirect pathway that leads to negative feedback for the medial subdivision of the CeA via activation of GABAergic neurons in the lateral subdivision of the CeA (CeAl) (Haubensak et al., 2010; Tye et al., 2011) . Although the mechanisms of the effects of this microcircuitry remain undefined, an increase in the release of CRF in CeAl has been shown to have the potential to enhance glutamatergic transmission (Silberman and Winder, 2013) . In a recent review of Henckens and colleagues (Henckens et al., 2016) , several convergent and contradicting findings as well as particularities and limitations were greatly discussed. Among the described particularities of CRF 1 and CRF 2 receptors that may explain our results, three of them should be here cited, to be concise: 1) all available agonists and antagonists have no absolute specificity for CRF receptors; 2) high ligand concentrations may act on both receptors; 3) signaling and downstream effects of CRF receptors are not fully known (Henckens et al., 2016) . Nevetheless, it is important to cite that labeling and distribution of CRF receptors in the brain is still limited. Still, the knowledge about the site of action (pre-or pos-synaptic) and cell type expression are important questions to be addressed (Henckens et al., 2016) . Noteworthy, the CRF system in stress-or emotion-related disorders is still a challenge and far to be simplistic. Although several studies have been conducted, the precise role of CRF receptors in emotional-related disorders is not well known. Moreover, due to the mechanistic complexity of CRF system, a broader role of CRF and its receptors should be considered.
Conclusion
The results of the present study suggest that blockade of CRF 1 and CRF 2 receptors in the BLA and CeA reduces the duration of TI behavior, probably due to decreased fear and/or anxiety. It is possible that this effect of specific CRF receptor antagonists can occur by reduction of endogenous activation of CRF induced by TI. Further, it was not due to altered spontaneous motor activity, which may non-specifically affect TI behavior. Our findings support the hypothesis that increased activation of CRF receptors, CRF 1 and CRF 2 , in the BLA and CeA is responsible for anxiogenic and fearful responses.
Author contributions
R.S contributed to the conception of the study, data collection, analysis and interpretation of data, as well as synthesis and manuscript writing. C.R.A.L.P. contributed to the conception of the study, performed the experimental design, interpretation of the data and manuscript writing. All authors read, approved and are in agreement for the final draft of this manuscript.
Conflicts of interest
The authors declare no conflicts of interests related to this study.
